<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32138555</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1-2</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Reliability and validity of speech &amp; pause measures during passage reading in ALS.</ArticleTitle><Pagination><StartPage>42</StartPage><EndPage>50</EndPage><MedlinePgn>42-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2019.1697888</ELocationID><Abstract><AbstractText><i>Objective:</i> The use of speech measures is becoming a common practice in the assessment of bulbar disease progression in amyotrophic lateral sclerosis (ALS). This study aimed to establish psychometric properties (e.g. reliability, validity, sensitivity, specificity) of speech and pause timing measures during a standardized passage<i>. Methods:</i> A large number of passage recordings (ALS <i>N</i>&#x2009;=&#x2009;775; Neurotypical controls <i>N</i>&#x2009;=&#x2009;323) was analyzed using a semi-automatic method (Speech and Pause Analysis, SPA). <i>Results:</i> The results revealed acceptable reliability of the speech and pause measures across repeated recording by the control participants. Strong construct validity was established via significant group differences between patients and controls and correlation statistics with clinical measures of overall ALS and bulbar disease severity. Speaking rate, pause events, and mean pause duration were able to detect ALS participants at the presymptomatic stage of bulbar disease with a good discrimination ability (AUC 0.81). <i>Conclusions:</i> Based on the current psychometric evaluation, performing passage recording and speech and pause timing analysis was deemed useful for detecting early and progressive changes associated with bulbar ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barnett</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto and University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Jordan R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-1464-1373</Identifier><AffiliationInfo><Affiliation>Department of Communication Sciences and Disorders, MGH Institute of Health Professions, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Speech and Hearing Biosciences and Technology Program, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marzouqah</LastName><ForeName>Reeman</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Speech-Language Pathology, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stipancic</LastName><ForeName>Kaila L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Communication Sciences and Disorders, MGH Institute of Health Professions, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Department of Neurology, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA,.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korngut</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute, Neurosurgery, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoesmith</LastName><ForeName>Christen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briemberg</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Neurology, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahao</LastName><ForeName>Agessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1142-2842</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalra</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, University of Alberta, Edmonton, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>L.C. Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, University of Toronto, Toronto, Canada, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yunusova</LastName><ForeName>Yana</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2353-2275</Identifier><AffiliationInfo><Affiliation>Department of Speech-Language Pathology, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Toronto Rehabilitation Institute, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DC009890</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DC013547</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DC017291</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Canadian Institutes for Health Research</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="Y">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011932" MajorTopicYN="Y">Reading</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013060" MajorTopicYN="N">Speech</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013068" MajorTopicYN="N">Speech Production Measurement</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bulbar ALS</Keyword><Keyword MajorTopicYN="N">passage reading</Keyword><Keyword MajorTopicYN="N">pauses</Keyword><Keyword MajorTopicYN="N">reliability</Keyword><Keyword MajorTopicYN="N">speaking rate</Keyword><Keyword MajorTopicYN="N">validity</Keyword></KeywordList><CoiStatement><b>Disclosure of interest:</b> The authors report no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32138555</ArticleId><ArticleId IdType="mid">NIHMS1547762</ArticleId><ArticleId IdType="pmc">PMC7080316</ArticleId><ArticleId IdType="doi">10.1080/21678421.2019.1697888</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hecht M, Hillemacher T, Grasel E, Tigges S, Winterholler M, Heuss D, et al. Subjective experience and coping in ALS. ALS Other Mot Neuron Disord. 2002;3:225&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12710513</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Boylan K, Jeromin A, Rutkove SB, Berry J, Atassi N, et al. ALS biomarkers for therapy development: State of the field and future directions. Muscle and Nerve. 2016;53(2):169&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718795</ArticleId><ArticleId IdType="pubmed">26574709</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunusova Y, Plowman EK, Green JR, Barnett C, Bede P. Clinical measures of bulbar dysfunction in ALS. Front Neurol. 2019;10:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389633</ArticleId><ArticleId IdType="pubmed">30837936</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunusova Y, Ansari J, Ramirez J, Shellikeri S, Stanisz GJ, Black SE, et al. Frontal anatomical correlates of cognitive and speech motor deficits in amyotrophic lateral sclerosis. Behav Neurol. 2019;2019:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6436339</ArticleId><ArticleId IdType="pubmed">31001362</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Plowman EK, Tabor LC, Wymer J, Pattee G. The evaluation of bulbar dysfunction in amyotrophic lateral sclerosis: Survey of clinical practice patterns in the United States. Amyotroph Lateral Scler Front Degener. 2017;18(5&#x2013;6):351&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7001984</ArticleId><ArticleId IdType="pubmed">28425762</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison K, Yunusova Y, Campbell T, Wang J, Berry J, Green JR. The diagnostic utility of patient-report and speech-language pathologists&#x2019; ratings for detecting the early onset of bulbar symptoms due to ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(5&#x2013;6):358&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5530595</ArticleId><ArticleId IdType="pubmed">28355886</ArticleId></ArticleIdList></Reference><Reference><Citation>Yorkston KM, Strand EA, Miller R, Hillel A, Smith K. Speech deterioration in amyotrophic lateral sclerosis: Implications for the timing of intervention. J Med Speech Lang Pathol. 1993;1:35&#x2013;46.</Citation></Reference><Reference><Citation>Ball, Laura J and Willis, Amy and Beukelman, David R and Pattee GL. A protocol for identification of early bulbar signs in amyotrophic lateral sclerosis. J Neurol Sci. 2001;191:43&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11676991</ArticleId></ArticleIdList></Reference><Reference><Citation>Yorkston KM, Beukelman D, Hakel MDM. Sentence Intelligibility Test. Lincoln, Nebraska,: Madonna Rehabilitation Hospital,; 2007.</Citation></Reference><Reference><Citation>Green JR, Yunusova Y, Kuruvilla MS, Wang J, Pattee GL, Synhorst L, et al. Bulbar and speech motor assessment in ALS: Challenges and future directions. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(7&#x2013;8):494&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833808</ArticleId><ArticleId IdType="pubmed">23898888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Kothalkar PV, Kim M, Bandini A, Cao B, Yunusova Y, et al. Automatic prediction of intelligible speaking rate for individuals with ALS from speech acoustic and articulatory samples. Int J Speech Lang Pathol. 2018. October;20(6):669&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6506394</ArticleId><ArticleId IdType="pubmed">30409057</ArticleId></ArticleIdList></Reference><Reference><Citation>Green JR, Beukelman DR, Ball LJ. Algorithmic estimation of pauses in extended speech samples of dysarthric and typical speech. J Med Speech Lang Pathol. 2004;12(4):149&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902000</ArticleId><ArticleId IdType="pubmed">20628555</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunusova Y, Graham NL, Shellikeri S, Phuong K, Kulkarni M, Rochon E, et al. Profiling speech and pausing in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). PLoS One. 2016;11(1):1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4720472</ArticleId><ArticleId IdType="pubmed">26789001</ArticleId></ArticleIdList></Reference><Reference><Citation>Green JR, Allison KM, Cordella C, Richburg BD, Pattee GL, Berry JD, et al. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis. Br J Clin Pharmacol. 2018;84:2849&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6256051</ArticleId><ArticleId IdType="pubmed">30152872</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Pioro E, Myers K, Sirdofsky M, Goslin K, Meekins G, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: The Nuedexta treatment trial. Neurotherapeutics. 2017;14:762&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5509619</ArticleId><ArticleId IdType="pubmed">28070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Stipancic KL, Yunusova Y, Berry JD, Green JR. Minimally detectable change and minimal clinically important difference of a decline in sentence intelligibility and speaking rate for individuals with amyotrophic lateral sclerosis. J Speech, Lang Hear Res. 2018;61(11):2757&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6693567</ArticleId><ArticleId IdType="pubmed">30383220</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2000;1(5):293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y-T, Green JR, Nip ISB, Kent RD, Kent JF, and Ullman C, Accuracy of perceptually based and acoustically based inspiratory loci in reading. Behavior Research Methods, Instruments &amp; Computers, 2010. 43(3): p. 791&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3645855</ArticleId><ArticleId IdType="pubmed">20805602</ArticleId></ArticleIdList></Reference><Reference><Citation>Portney Leslie Gross MPW. Foundations of Clincial Research. Prentice Hall; 2009. 892.</Citation></Reference><Reference><Citation>Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">2868172</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaton DE, Bombardier C, Katz JN, Wright JG. A taxonomy for responsiveness. J Clin Epidemiol. 2001. December;54(12):1204&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750189</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakdash JZ, Marusich LR. Repeated measures correlation. Front Psychol. 2017;8:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell F Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. J Am Stat Assoc. 2001;</Citation></Reference><Reference><Citation>Team RC. R: A language and environment for statistical computing. R Found Stat Comput; 2013;</Citation></Reference><Reference><Citation>Yorkston K, Beukelman D, Hakel M. Speech Intelligibility Test (SIT) for Windows [computer software]. Lincoln, Nebraska, USA: Madonna Rehabilitation Hospital; 2007.</Citation></Reference><Reference><Citation>Mitchell HL, Hoit JD, Watson PJ. Cognitive-linguistic demands and speech breathing. J Speech, Lang Hear Res. 1996;39(1):93&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">8820701</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>